Reyataz label
Interaction Color Code
Clinical Bottom Line
Adjust dosing to avoid reduced levels of atazanavir
Drug 1
Drug 1 dose
300 mg QPM with 100 mg ritonavir QPM on d 7-16, 17-23
Drug 1 effect
Atazanavir AUC decreased 42%, Cmax decreased 39%, Cmin decreased 46%
Drug 2
Drug 2 dose
20 mg daily on d 17-23
Clinical Effects
Potential loss of antiretroviral efficacy
Management
Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Alternative Agents
H2 receptor antagonists
Import ID
780
